Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit.

doi:10.1200/PO.21.00413

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit.

JCO precision oncology - 1 Jul 2022

Barroso-Sousa Romualdo, Forman Juliet, Collier Katharine, Weber Zachary T, Jammihal Tejas R, Kao Katrina Z, Richardson Edward T, Keenan Tanya, Cohen Ofir, Manos Michael P, Brennick Ryan C, Ott Patrick A, Hodi F Stephen, Dillon Deborah A, Attaya Victoria, O'Meara Tess, Lin Nancy U, Van Allen Eliezer M, Rodig Scott, Winer Eric P, Mittendorf Elizabeth A, Wu Catherine J, Wagle Nikhil, Stover Daniel G, Shukla Sachet A, Tolaney Sara M

Abstract excerpt

PURPOSE: In metastatic triple-negative breast cancer (mTNBC), consistent biomarkers of immune checkpoint inhibitor (ICI) therapy benefit remain elusive. We evaluated the immune, genomic, and transcriptomic landscape of mTNBC in patients treated with ICIs. METHODS: We identified 29 patients with mTNBC treated with pembrolizumab or atezolizumab, either alone (n = 9) or in combination with chemotherapy (n = 14) or...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cancer Cells and Metastasis

Share to Cancer Immunotherapy and Biomarkers

Share to Ferroptosis and cancer prognosis

Share to Immune Checkpoint Inhibitors

Share to Mutation

Share to Progression-Free Survival

Share to Triple Negative Breast Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 35797509
DOI: 10.1200/PO.21.00413
PMCID: PMC9848556

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit.PMID 35797509Read ↗

Comprehensive Profiling of Poor-Risk Paired Primary and Recurrent Triple-Negative Breast Cancers Reveals Immune Phenotype ShiftsSemantic proximity Read ↗

Tumor immune microenvironment and genomic evolution in a patient with metastatic triple negative breast cancer and a complete response to atezolizumab.Semantic proximity Read ↗

Differential peripheral immune dynamics underlie therapeutic response to chemotherapy and chemo-immunotherapy in triple-negative breast cancerSemantic proximity Read ↗

A Comprehensive Immunologic Portrait of Triple-Negative Breast CancerSemantic proximity Read ↗

Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer.Semantic proximity Read ↗

Immune Milieu and Genomic Alterations Set the Triple-Negative Breast Cancer Immunomodulatory Subtype Tumor BehaviorSemantic proximity Read ↗

Genomic Features of Rapid Versus Late Relapse in Triple Negative Breast Cancer Semantic proximity Read ↗

Converging and evolving immuno-genomic routes toward immune escape in breast cancerSemantic proximity Read ↗

Triple negative breast cancer (TNBC): Non-genetic tumor heterogeneity and immune microenvironment: Emerging treatment optionsSemantic proximity Read ↗

Genomic and transcriptomic profiles associated with response to eribulin and nivolumab combination in HER-2-negative metastatic breast cancer.Semantic proximity Read ↗

The Great Immune Escape: Understanding the Divergent Immune Response in Breast Cancer SubtypesSemantic proximity Read ↗

DNA barcoding reveals ongoing immunoediting of clonal cancer populations during metastatic progression and immunotherapy responseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.